Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 6/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9755798 | 0.80 | ABCB1 (0.48) | CPA1ABCB1NPC1RAB9A | |
| SCHEMBL12373434 | 0.80 | CPA1 (0.50) | CPA1ABCB1NPC1RAB9A | |
| SCHEMBL9755795 | 0.80 | ABCB1 (0.48) | CPA1ABCB1NPC1RAB9A | |
| SCHEMBL27875595 | 0.79 | CPA1 (0.62) | CPA1NPC1 | |
| SCHEMBL4302074 | 0.79 | CPA1 (0.37) | CPA1 | |
| Hydrochloric Acid SCHEMBL4841802 | 0.78 | ABCB1 (0.46) | CPA1ABCB1NPC1RAB9A | |
| SCHEMBL7506611 | 0.77 | ABCB1 (0.48) | ABCB1NPC1RAB9A | |
| SCHEMBL27750768 | 0.77 | L3MBTL1 (0.53) | CPA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27730273 | 0.77 | L3MBTL1 (0.53) | CPA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27730272 | 0.77 | L3MBTL1 (0.53) | CPA1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | SPERO THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12528837-B2 | Aryl substituted polymyxin derivatives | SPERO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| CN-118878638-A | Polymyxin compound, pharmaceutical composition and application thereof | 云顶新耀医药科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-112789287-B | Compounds of formula (I) | 云顶新耀医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4316504-A2 | COMPOUNDS | Spero Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3810633-B1 | COMPOUNDS | SPERO THERAPEUTICS INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230012121-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11459357-B2 | Polymyxin compounds | SPERO THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210246169-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| CN-112789287-A | Compound (I) | 斯佩罗治疗公司 | 2021-05-11 | — | — | CN | disclosed |
| US-6861530-B2 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20020137770-A1 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137770-A1 | Piperidine derivatives | CIP2A, PARP2, TP53 | CPA1 3469/4885ABCB1 237/4885NPC1 1427/4885 |
| US-12528837-B2 | Aryl substituted polymyxin derivatives | PTMS, PNISR, BCAT2 | CPA1 3427/4885ABCB1 3571/4885NPC1 4063/4885 |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | PTMS, FPR1, BCAT2 | CPA1 3039/4885ABCB1 2436/4885NPC1 2851/4885 |
| US-20230012121-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPL21 | CPA1 2831/4885ABCB1 1084/4885NPC1 3341/4885 |
| US-11459357-B2 | Polymyxin compounds | MRPL37, MRPS18A, PNISR | CPA1 2490/4885ABCB1 1434/4885NPC1 3973/4885 |
| US-20210246169-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPS35 | CPA1 2607/4885ABCB1 1133/4885NPC1 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.